Moreover, the decreased expression of TRPM6 in cancer patients treated with EGFR targeted therapies (e.g., cetuximab) seems to positively contribute to the oncologic efficacy of these therapies, as decreased magnesium availability inhibits cell proliferation and slows down tumor growth79,80. Here, EGFR is linked to neoplasm.